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Background
There is no current treatment alternative for patients
with FMF whose disease is resistant to, or do not toler-
ate colchicine. Since pyrin has an important role in IL-
1b regulation we hypothesize that IL-1 inhibition will
decrease the number of FMF attacks in these patients.
Aim
To determine if rilonacept, a fusion protein that binds
and neutralizes IL-1, decreases the number of FMF
attacks compared to placebo.
Methods
Subjects were FMF patients ≥4 years of age recruited at
6 U.S. sites, who had at least 1 FMF attack per month
despite receiving adequate doses of, or who were intol-
erant of colchicine. Subjects received two 3-month
courses of rilonacept (Arm A) at 2.2 mg/kg (max 160
mg) by weekly SC injection and two 3-month courses of
placebo (Arm B). Patients were randomized to 1 of 4
treatment sequences (ABAB, BABA, ABBA, BAAB).
Escape visits were allowed to permit switching arms
(blinding was maintained) for patients with at least 2
attacks within a course. The primary outcome was the
difference of FMF attacks between rilonacept and pla-
cebo courses with responders defined as subjects with a
>40% difference. Results were analyzed by paired t-and
signed rank tests.
Results
Fourteen subjects were randomized, 8 males and 6
females, mean (±SD) age 24.4±11.8 years (range 4.5-
47.3; 4 patients <18 years), disease duration 17.5±12.6
yrs, with a baseline of 3.1±2.0 attacks per month. Eleven
completed the full study and 3 dropped out (1 due to
lack of efficacy, 1 due to distance from study site and 1
lost to follow-up). Among 12 patients who completed at
least 2 treatment courses the mean number of attacks
per month on rilonacept was 1.0±1.2 vs. 1.8±0.9 on pla-
cebo (P=0.021 by paired t-test and 0.027 by signed rank
test). There were 8 responders; all 4 non-responders
were adults. There were 2 respiratory infection SAEs, 1
on rilonacept and 1 on placebo. Injections site reactions
were significantly more frequent with rilonacept but no
differences were seen in other adverse events, including
infections.
Conclusions
Rilonacept significantly reduced the number of FMF
attacks and had an acceptable safety profile. IL-1 inhibi-
tion is a treatment option for most (especially children)
colchicine resistant FMF patients.
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